Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 4:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 10,850 matching trials from the live ClinicalTrials.gov search.
Conditions
Genetic Diseases, Inborn, Genetic Predisposition to Disease
Interventions
Standard of Care, GUÍA
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 21 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Conditions
Huntington's Disease
Interventions
SEN0014196
Drug
Lead sponsor
Siena Biotech S.p.A.
Industry
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • St Louis, Missouri + 4 more
Conditions
Skin; Deformity
Interventions
RECELL® Autologous Cell Harvesting Device, Telfa™ Clear and Xeroform™ dressings
Device · Other
Lead sponsor
Avita Medical
Industry
Eligibility
1 Year to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 4 more
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions
CliniMACS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Houston, Texas
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Skin Imaging to Inform Laser Treatments

NCT04336163
Conditions
Port-Wine Stain, Rosacea, Telangiectasia, Angioma
Interventions
Optical Coherence Tomography
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
4 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Irvine, California
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Lomecel-B medicinal signaling cells
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more
Conditions
Eczema, Dermatitis, Dermatitis, Atopic, Genetic Disease, Inborn, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, Skin Diseases, Skin Diseases, Eczematous, Skin Diseases, Genetic
Interventions
Care provided by general pediatrician, Care provided by pediatric dermatologist
Other
Lead sponsor
Yale University
Other
Eligibility
Up to 7 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 2 Interventional

Efalizumab for Eczema

NCT00146003
Conditions
Dermatitis, Atopic
Interventions
Efalizumab treatment
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Skin Laxity, Meibomian Gland Dysfunction
Interventions
THERMIeyes® 20 RF System
Device
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lynbrook, New York
Conditions
Hereditary Angioedemas
Interventions
No intervention
Other
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Phoenix, Arizona • Miami, Florida • Saint Charles, Illinois + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

BTL-785F Device for Non-invasive Reduction of Wrinkles

NCT05519124
Conditions
Wrinkle
Interventions
BTL-785-7
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
New York, New York • Youngstown, Ohio
Conditions
Autosomal Dominant Polycystic Kidney
Interventions
Daily caloric restriction, Standard advice control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Bone Marrow Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cardiac Amyloidosis
Interventions
EchoNet-LVH screening for cardiac amyloidosis
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers

NCT00531882
Conditions
Cystic Fibrosis
Interventions
Pioglitazone, Simvastatin, Ibuprofen
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Cleveland, Ohio
Terminated Phase 3 Interventional Results available

Study of Ataluren (PTC124) in Cystic Fibrosis

NCT02107859
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Long Beach, California • Aurora, Colorado + 4 more
Conditions
Cystic Fibrosis
Interventions
Aerobic exercise, Resistance exercise, Flexibility and postural exercise, Balance exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Birmingham, Alabama
Active, not recruiting No phase listed Observational

ALTERRA Post-Approval Study

NCT05378386
Conditions
Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Interventions
Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Conditions
Congenital Heart Disease, Sepsis, Infection
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 5 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Water prescription
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Kansas
Not listed No phase listed Observational Accepts healthy volunteers

Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease

NCT06065605
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rockville, Maryland • Fairfax, Virginia
Conditions
Congenital Heart Disease
Interventions
EQUANOX Advance 8004CB sensor
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 3 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington